Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?

Busse William W., Dahl Ronald, Jenkins Christine, Cruz Alvaro A.

Source: Eur Respir Rev 2015; 25: 54-64
Journal Issue: March
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Busse William W., Dahl Ronald, Jenkins Christine, Cruz Alvaro A.. Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?. Eur Respir Rev 2015; 25: 54-64

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017

Is there a problem with short-acting beta-2 agonist monotherapy in asthma?
Source: Virtual Congress 2020 – Airway diseases
Year: 2020


The efficacy and safety of long-acting muscarinic antagonist treatment for COPD
Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma
Year: 2019


Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Emerging inhaled bronchodilators: an update
Source: Eur Respir J 2009; 34: 757
Year: 2009



Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014


Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007


Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma?
Source: Eur Respir J 2001; 17: 1059-1061
Year: 2001


Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma
Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring
Year: 2010

Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

First line anti-inflammatory treatment for asthma: inhaled steroid or leukotriene antagonist?
Source: Eur Respir J 2002; 20: Suppl. 38, 93s
Year: 2002

Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

What predicts short-acting beta agonist (SABA) monotherapy use in children?
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Long-acting β2-agonists provide greater benefit compared to leukotriene antagonists when added to inhaled corticosteroids in patients with symptomatic asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004

First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Combining corticosteroids and NK1R antagonists: A new drugs combination to treat allergic diseases
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012

Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008


Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010